RefleXion Medical is a developer of biologically-guided radiotherapy systems for patients with cancer.

RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),  stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.

RefleXion Medical

Regulatory Affairs Specialist

Principal Regulatory Affairs Specialist

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.

Illumina

Sr. Regulatory Affairs Specialist - Post Market Compliance

atecspine

Sr. Regulatory Affairs Specialist (Radiology/Medical Imaging)

PROCEPT BioRobotics is a surgical robotics company that develops water-based robotic systems for prostate surgery.

PROCEPT is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

PROCEPT BioRobotics

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of av√ü6 and av√ü1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of av√ü1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

Pliant Therapeutics

Penumbra develops clinically beneficial products that help patients suffering from stroke and other neurovascular diseases.

Penumbra, Inc. develops clinically beneficial products that help patients suffering from stroke and other neurovascular diseases. It offers Penumbra System, an ischemic stroke device platform; Penumbra Coil 400 that allows rapid packing of aneurysms; 5MAX ACE, a clot extraction device for engaging and removing blood clots causing an acute ischemic stroke; and Neuron System, a family of access catheters to enable therapies to be delivered to blood vessels high up in the brain. The company sells its products in North and South America, Europe, Australia, and Asia. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

Penumbra

Regulatory Affairs Specialist I

The Honest Company is a consumer products company that offers baby, personal care, and beauty products.

The Honest Company creates eco-friendly, convenient, and affordable products for babies and homes. Its products include eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products all packed in convenient bundles that can be customized, personalized, and conveniently shipped whenever needed.

The Honest Company

Harry's is a developer of an online platform used to sell shaving equipment and accessories for men.

Harry's is a developer of an online platform used to sell shaving equipment and accessories for men. It designs and manufactures its own line of razors and replacement blades, as well as other shaving consumables, and offers its products a-la-carte via its online store or through a subscription model that enables consumers to meet their grooming essentials need online. The company was founded in 2013 and is headquartered in New York.

Harry's

Third Pole develops products that generate and deliver electric nitric oxide for hospital, ambulatory, and home use.

Third Pole core technology is an innovative, clean, tankless inhaled Nitric Oxide (NO) proven equivalent to marketed tank-gas in the lab. Nitric oxide saves hypoxic newborns, but it is only available in a limited number of countries, for those who can afford it, by physicians who have access to the product.

Location

Company Stage

Age of Data

Experience

Industry

Company

Regulatory Affairs Specialist

RefleXion Medical

$160k - $195k

$160,000 - $195,000

Illumina

$87k - $130k

$86,500 - $129,700

atecspine

$101k - $129k

$101,300 - $128,850

PROCEPT BioRobotics

$85k - $121k

$85,000 - $121,000

Pliant Therapeutics

$75k - $101k

$74,809 - $101,095

Penumbra

$77k - $94k

$76,890 - $94,073

The Honest Company

$66k - $92k

$66,000 - $92,000

Harry's

$85k - $91k

$85,000 - $91,000

Third Pole

N/A

N/A

clinchoice

N/A

N/A

biofiredefense

N/A

N/A

acadia

N/A

N/A